Appropriate and inappropriate use of immunotherapy

DuBuske, L.M.

doi:10.1016/s1081-1206(10)62196-5

Cited by 19 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…with respect to the youngest age at which allergen immunotherapy should be considered" remains an open-ended research question. 22 In clinical practice, however, prescription of specific immunotherapy is gaining ground in pediatrics. In many regions of Italy, allergy vaccines are supplied free of charge and immunotherapy is administered in hospital for a minimal fee.…”

Section: Introductionmentioning

confidence: 99%

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Fiocchi¹,

Pajno

Grutta³

et al. 2005

Annals of Allergy, Asthma & Immunology

113

View full text Add to dashboard Cite

Background:The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years.Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years.Methods: Sixty-five children (51 boys and 14 girls; age range, 38 -80 months; mean Ϯ SD age, 60 Ϯ 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old.Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups.Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.Ann Allergy Asthma Immunol. 2005;95:254-258.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Fiocchi¹,

Pajno

Grutta³

et al. 2005

Annals of Allergy, Asthma & Immunology

113

View full text Add to dashboard Cite

show abstract

“…Specific immunotherapy (SIT) is an aetiological treatment for allergic diseases, whose clinical efficacy is well documented [1][2][3][4][5]. Nowadays, the most important problem concerning practical SIT is safety [6].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy safety: a prospective multi‐centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases

Moreno

Cuesta‐Herranz

Fernández-Távora³

et al. 2004

Clin Experimental Allergy

104

View full text Add to dashboard Cite

show abstract

“…It is necessary to avoid or reduce stimuli that may cause the acute aggravation of asthma and to apply appropriate drug administration in order to manage the disease effectively (Mathison & Koziol, 2000). Immunotherapy, applied when drug therapy is not inappropriate, requires the understanding of its principles, the frequency of injections, therapeutic period, symptoms of side effects and the importance of compliance with health care regimens (DuBuske, 2001).…”

Section: Discussionmentioning

confidence: 99%